About Laurus Labs
Laurus Labs is a leading Indian pharmaceutical and biotechnology company focused on Active Pharmaceutical Ingredients (APIs), Finished Dosage Formulations (FDF), Contract Development & Manufacturing Organization (CDMO) services, and biotechnology products. The company supplies medicines to more than 80 countries and has emerged as a major player in the global pharmaceutical supply chain.
Fundamental Analysis
FY26 Financial Performance
| Metric | FY26 |
|---|---|
| Revenue | ₹6,813 Crore |
| Revenue Growth | 23% YoY |
| EBITDA | ₹1,826 Crore |
| EBITDA Margin | 26.8% |
| Net Profit | ₹889 Crore |
| Net Profit Growth | 148% YoY |
| EPS | ₹16.4 |
Laurus Labs delivered an excellent FY26 performance, driven by strong growth in its CDMO business, generics segment, and improved operating margins. Revenue grew 23% while net profit surged 148% year-on-year.
Key Strengths
✅ Strong presence in APIs, formulations, and CDMO services.
✅ Growing global pharmaceutical customer base.
✅ Beneficiary of the China+1 manufacturing shift.
✅ Significant investments in biologics, gene therapy, and advanced pharmaceutical manufacturing.
✅ Strong R&D capabilities and regulatory approvals.
Growth Drivers
1. CDMO Expansion
The CDMO segment has become the biggest growth driver for Laurus Labs. New chemical entity projects, manufacturing capacity expansion, and global partnerships continue to support long-term growth.
2. Generics Business
The company's formulations and API businesses continue to benefit from strong demand in antiretroviral medicines and regulated markets.
3. New Facilities
Laurus Labs is investing in gene therapy, antibody-drug conjugates (ADC), and microbial fermentation facilities to strengthen future growth opportunities.
Risks
⚠ Dependence on global pharmaceutical demand.
⚠ Regulatory risks from USFDA and international agencies.
⚠ Pricing pressure in generic medicines.
⚠ High competition in API and CDMO segments.
Technical Analysis (June 2026)
Trend
- Long-Term Trend: Bullish
- Medium-Term Trend: Strong Bullish
- Short-Term Trend: Positive with periodic profit booking
The stock has witnessed a strong recovery due to improving profitability, margin expansion, and strong execution in the CDMO segment.
Key Support & Resistance Levels
| Level Type | Price |
|---|---|
| Resistance 1 | ₹1,420 |
| Resistance 2 | ₹1,500 |
| Resistance 3 | ₹1,600 |
| Support 1 | ₹1,300 |
| Support 2 | ₹1,220 |
| Support 3 | ₹1,150 |
Technical View
- Above ₹1,420: Fresh bullish momentum may continue.
- Above ₹1,500: Potential breakout zone.
- Below ₹1,300: Short-term consolidation may continue.
- Long-term structure remains positive due to strong earnings growth.
Investment Positives
Why Investors Like Laurus Labs
✔ Strong earnings turnaround.
✔ Rapid growth in CDMO business.
✔ Expanding global customer relationships.
✔ Exposure to high-growth biotech opportunities.
✔ Strong operating margin improvement.
✔ Long-term pharmaceutical manufacturing opportunity.
Investment Outlook
Laurus Labs has transformed from a traditional API company into a diversified pharmaceutical and biotech player. Its strong FY26 results, expanding CDMO business, improving margins, and capacity additions position the company well for future growth. Investors should monitor execution of expansion projects and developments in regulated markets.
Conclusion
Laurus Labs remains one of the promising pharmaceutical growth stocks in India. With strong revenue growth, significant profit expansion, a rapidly growing CDMO business, and investments in future technologies, the company offers attractive long-term potential for investors seeking exposure to the healthcare sector.
SEO Keywords
Laurus Labs share analysis 2026, Laurus Labs fundamental analysis, Laurus Labs technical analysis, LAURUSLABS share target, Laurus Labs stock review, Laurus Labs FY26 results, Laurus Labs CDMO business, Laurus Labs long term investment, pharma stocks India, Laurus Labs support resistance levels.
0 Comments